News
VERA
30.03
-1.89%
-0.58
Aurinia: Paying For Growth That Is Already Fading
Seeking Alpha · 16h ago
Weekly Report: what happened at VERA last week (1102-1106)?
Weekly Report · 1d ago
Bank of America Securities Remains a Buy on Vera Therapeutics (VERA)
TipRanks · 3d ago
Vera Therapeutics Price Target Cut to $29.00/Share From $34.00 by Wedbush
Dow Jones · 4d ago
Vera Therapeutics Is Maintained at Neutral by Wedbush
Dow Jones · 4d ago
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $29
Benzinga · 4d ago
Vera Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 4d ago
Vera Therapeutics Price Target Cut to $66.00/Share From $76.00 by Guggenheim
Dow Jones · 4d ago
Guggenheim Maintains Buy on Vera Therapeutics, Lowers Price Target to $66
Benzinga · 4d ago
Cantor Fitzgerald Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
TipRanks · 4d ago
Vera Therapeutics Price Target Cut to $75.00/Share From $90.00 by HC Wainwright & Co.
Dow Jones · 4d ago
Vera Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $75
Benzinga · 4d ago
Vera Therapeutics Reports Third Quarter 2026 Financial Results
NASDAQ · 4d ago
Vera Therapeutics price target lowered to $75 from $90 at H.C. Wainwright
TipRanks · 4d ago
Press Release: Vera Therapeutics Provides -2-
Dow Jones · 5d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 11/02 16:01
Weekly Report: what happened at VERA last week (1026-1030)?
Weekly Report · 11/02 10:01
Leerink Partners Reaffirms Their Hold Rating on Vera Therapeutics (VERA)
TipRanks · 10/27 13:36
Weekly Report: what happened at VERA last week (1019-1023)?
Weekly Report · 10/26 10:01
More
Webull provides a variety of real-time VERA stock news. You can receive the latest news about Vera Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VERA
Vera Therapeutics, Inc. is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.